Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in... see more

Recent & Breaking News (TSXV:VPT)

Ventripoint Announces New Vice-President of Sales and Marketing

Marketwired May 30, 2013

Ventripoint Announces New Vice-President of Sales and Marketing

Marketwired May 30, 2013

VentriPoint Announces Closing of Private Placement and Proposed Issuance of Shares for Debt

Marketwired May 23, 2013

VentriPoint Announces Closing of Private Placement and Proposed Issuance of Shares for Debt

Marketwired May 23, 2013

VentriPoint Announces Private Placements

Marketwired May 6, 2013

VentriPoint Announces Private Placements

Marketwired May 6, 2013

VentriPoint Receives Health Canada License for the NRV(TM) Application for Non-Specific Heart Disease

Marketwired April 30, 2013

VentriPoint Receives Health Canada License for the NRV(TM) Application for Non-Specific Heart Disease

Marketwired April 30, 2013

VentriPoint Receives Request for Clarification to 510 (k) Submission for Pulmonary Arterial Hypertension

Marketwired April 25, 2013

VentriPoint Receives Request for Clarification to 510 (k) Submission for Pulmonary Arterial Hypertension

Marketwired April 25, 2013

VentriPoint Announces Closing of Offering

Marketwired April 22, 2013

VentriPoint Receives CE Mark for Major Expansion of Its VMS(TM) Platform for Right Heart Analysis

Marketwired April 17, 2013

VentriPoint Announces First Closing of Offering And Issuance of Shares for Debt

Marketwired April 1, 2013

VentriPoint Applies for European and Canadian Approvals for A New Application for Non-Specific Heart Disease

MarketWire Canada March 21, 2013

VentriPoint Applies for European and Canadian Approvals for A New Application for Non-Specific Heart Disease

Marketwired March 21, 2013

VentriPoint Announces $2 Million Unit Private Placement

MarketWire Canada March 4, 2013

Avalon Rare Metals, Zenyatta Ventures and Ventripoint Diagnostics Kick-Off Season 2 of the Next Biggest Winner TV Show

MarketWire Canada March 1, 2013

VentriPoint Receives US-FDA Acceptance of 510 (K) Submission for Pulmonary Arterial Hypertension

MarketWire Canada March 1, 2013

VentriPoint Completes Development of VMS(TM) Product to Analyse Cardiac MRI

MarketWire Canada February 25, 2013

VentriPoint Announces 3D Ultrasound Heart Analysis System and Prepares for Clinical Release

MarketWire Canada February 21, 2013